Insulin degludec manufacturers
- Insulin Degludec
-
- $3.00 / 25KG
-
2025-10-13
- CAS:844439-96-9
- Min. Order: 0.1KG
- Purity: 99%
- Supply Ability: g-kg-tons, free sample is available
- Insulin degludec
-
- $30.00/ BOX
-
2024-03-31
- CAS:844439-96-9
- Min. Order: 10BOX
- Purity: 99
- Supply Ability: 20TONS
|
| | Insulin degludec Basic information |
| Product Name: | Insulin degludec | | Synonyms: | Insulin degludec;Insulin degludec USP/EP/BP;degludec insulin;Insulin Degludec/ Degludec Insulin;Research Grade Insulin Degludec | | CAS: | 844439-96-9 | | MF: | C274H411N65O81S6 | | MW: | 6103.97204 | | EINECS: | | | Product Categories: | API | | Mol File: | 844439-96-9.mol |  |
| | Insulin degludec Chemical Properties |
| storage temp. | Store at -20°C | | form | Solid | | color | White to off-white | | InChIKey | FYZPCMFQCNBYCY-WIWKJPBBSA-N |
| | Insulin degludec Usage And Synthesis |
| Uses | Insulin degludec is an ultra-long-acting form of insulin used for the research of hyperglycemia caused by type 1 and type 2 dabetes. Insulin degludec shows binding efficiency with an IC50 value of 19.59 nM for insulin receptor. Insulin degludec can be used for the research of type 1 and type 2 diabetes[1][2]. | | in vivo | Insulin degludec (5 U/kg; s.c. once daily for 30 days) affects glucose homeostasis and liver metabolism in diabetic mice undergoing insulin-induced hypoglycemia[1]. | Animal Model: | Male Swiss mice with diabetes[1] | | Dosage: | 5 U/kg | | Administration: | Subcutaneous injection; 5 U/kg once daily for 30 days | | Result: | Showed a fast response to insulin-induced hypoglycemia with a glycemic level at or slightly under 100 mg/dl after 60 min and this response effect can be abolished by cortisol. Diminished rates of glucose production and showed a low lactate production in livers. Increased the number of hepatocytes. |
| | References | [1] Bataglini C, et al. Insulin degludec and glutamine dipeptide modify glucose homeostasis and liver metabolism in diabetic mice undergoing insulin-induced hypoglycemia. J Appl Biomed. 2021 Dec;19(4):210-219. DOI:10.32725/jab.2021.025
[2] Hartmann T, et al. Effect of the long-acting insulin analogues glargine and degludec on cardiomyocyte cell signalling and function. Cardiovasc Diabetol. 2016 Jul DOI:10.1186/s12933-016-0410-9 |
| | Insulin degludec Preparation Products And Raw materials |
|